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Is There a Role for Repeated Cardioversion in Patients with
Recurrent Atrial Fibrillation?
HUNG-FAT TSE, CHU-PAK LAU
From Cardiology Division, Department of Medicine, The University of Hong Kong, Queen Mary Hospital,
Hong Kong
TSE and LAU: Is There a Role for Repeated Cardioversion in Patients with Recurrent Atrial Fibrillation?
Recent clinical and experimental studies have demonstrated that atrial fibrillation (AF) alters the electrical and
mechanical remodeling of the atrium which subsequently promote the maintenance and recurrence of AF. If atrial
remodeling can be prevented with prompt and repeated cardioversion, the likelihood of AF recurrence may be
reduced. Recent clinical studies have demonstrated that the strategies of transesophageal echocardiography facilitated
early cardioversion and early repeated cardioversion may be clinically valuable in some patients who have persistent
AF and recurrence of arrhythmia after the initial cardioversion. Furthermore, the use an implantable atrial defibrillator
(IAD) for early repeated device-based cardioversion to maintain sinus rhythm appears to be safe and clinically
feasible. Early cardioversion by IAD reduces AF burden, reverses atrial remodeling and prevents subsequent AF
recurrence in selected patients without structural heart disease implanted with this device, indicating possible "sinus
rhythm begets sinus rhythm". Despite this encouraging initial observation, further long-term clinical studies in a
larger patient population are needed to confirm this finding. Furthermore, whether the use of IAD in the fully
automatic mode to provide immediate termination of AF episodes could intensify the potential beneficial effect and
the clinical efficacy of this approach in patients with structural heart disease remains to be evaluated. (J HK Coll
Cardiol 2003;11:90-96)
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Background
Atrial fibrillation (AF) is the commonest
sustained arrhythmia, and is associated with an
increased mortality due to higher incidence of strokes
and heart failure.1,2 Together with heart failure, AF has
been described as the two emerging epidemic of cardiovascular disease due to the aging of the population.3
Furthermore, individuals with AF or heart failure who
subsequently develop the other condition are associated
with a poor prognosis.4 Clinical management for patients
with AF varies. The commonest strategy for
management of AF is anticoagulation and either rate
control or rhythm control with antiarrhythmic
medications. Neither of these two strategies is ideal.
Rate control alone does not eliminate symptoms in a
significant proportion of AF patients, and antiarrhythmic
drugs often do not maintain sinus rhythm and may lead
to life-threatening ventricular arrhythmias.5,6 In patients
who remain symptomatic despite adequate rate control,
chemical or electrical cardioversion is commonly
performed to relieve symptoms and improve cardiac
performance. Nevertheless, long-term maintenance of
sinus rhythm remains a challenge. The purpose of this
article is to discuss the potential role of repeated
cardioversion to restore sinus rhythm for maintenance
of sinus rhythm in patients with persistent AF.

Electrical and Mechanical
Remodeling in AF
Prior clinical observations have suggested that
AF is a progressive disease which has a tendency to
become persistent over time. A significant proportion
of patients with lone AF without any structural heart
disease developed persistent AF during long-term
follow-up.7 Furthermore, the success rate of pharmacological and electrical cardioversion, and subsequent
maintenance of sinus rhythm are reduced with
increasing duration of AF.8-10 In patients with structural
heart diseases, the progression of AF can be related to
the development of underlying atrial substrate such as
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fibrosis as a result of underlying heart diseases or aging.
In turn, atrial fibrosis is associated with slowing and
dispersion of conduction and an increase in
heterogeneity of refractoriness to promote the
development of AF.11,12 These notions comply with the
fact that the prevalence of AF increases with age, in
particular persistent AF.
Recently, another important concept of "AF
begets AF" is emerging from the experimental model
of AF.13-15 These studies demonstrated that repetitive
induction of AF by atrial burst pacing resulted in atrial
remodeling by which atrial changes during AF promote
the persistence and recurrence of AF. Understanding
the mechanisms of atrial remodeling has provided
important insights into AF and its management. Atrial
remodeling is principally due to the rapid atrial rate and
is mediated by reduced L-type outward calcium current
and changes in calcium handling and cellular ultrastructure changes that result in atrial myocyte calcium
overload. Electrical remodeling with shortening of atrial
refractoriness develops within the first days of AF and
contributes to the increase in stability of the arrhythmia.
However, the occurrence of sustained AF also depends
on other mechanisms since the duration and persistence
of AF continues to increase after electrical remodeling
has been completed. Atrial mechanical remodeling also
occurs at the same time course as electrical remodeling
but progress over time. Atrial mechanical dysfunction
not only enhances the risk of atrial thrombus formation,
but also enhances atrial dilatation by increasing the
compliance of the fibrillating atrium. Chronic atrial
stretch induces activation of numerous signaling
pathways leading to cellular hypertrophy, fibroblast
proliferation and tissue fibrosis. The resulting
electroanatomical substrate in dilated atria is
characterized by increased non-uniform anisotropy and
macroscopic slowing of conduction, promoting
reentrant circuits in the atria. These electrical and
mechanical changes during AF promote the persistence
of the arrhythmia.15 Clinical studies also confirmed these
experimental findings and demonstrated the presence
of atrial electrical and mechanical remodeling in patients
with AF.16-18
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Following conversion of AF, reverse remodeling
of atrial electrical properties occurred in animal model
of AF. 19 The recovery of atrial electrophysiological
properties included a progressive recovery of shortening
and maladaptation of atrial refractoriness, and decrease
of duration and episodes of reinduced AF. Hobbs et al20
measured the atrial refractory period in patients
underwent repeated internal cardioversion for persistent.
After successful cardioversion, the changes in atrial
electrophysiology associated with chronic AF in humans
are reversible and that the extent of this reversal is
dependent on the duration of sinus rhythm after
cardioversion. However, the atrial mechanical function
may require 1 week or more to recover, and is also
dependent on the duration of AF before cardioversion.21
These effects may well explain the high rate of early
recurrence following conversion of AF. A corollary of
the notion that 'AF begets AF' is the idea that 'sinus
rhythm begets sinus rhythm'. In this respect, prompt
restoration of sinus rhythm once AF occurs should
rapidly restore physiologic hemodynamics, avoid atrial
remodeling that favor the maintenance of AF to reduce
arrhythmia recurrence, and minimize the risk of
stroke.

Early External Cardioversion
Prior clinical studies have demonstrated the
duration of AF is an important predictor for AF
recurrence. 8-10 Furthermore, when cardioversion is
performed within 48 hours of the onset of AF, the risks
of thromboembolism are lower than if cardioversion is
delayed, and the undesirable complications of
anticoagulation may be avoided.22 Therefore, early
cardioversion not only immediately relieves symptoms
and improves exercise capacity, but also has theoretical
advantage of avoiding the risk and inconvenience
associated with anticoagulation prior to cardioversion,
preventing atrial remodeling and may have a lower
recurrence rate. The conventional strategy of anticoagulation for 3 weeks before cardioversion always
lead to a much longer delayed in elective cardioversion.23
Recently, the use of transesophageal echocardiography
(TEE) to detect the presence of thrombi in the left atrial
appendage before cardioversion has facilitated early
cardioversion for AF. Clinical studies 24,25 have
demonstrated the TEE-facilitated cardioversion is a safe
and convenient alternative to the conventional approach
(Table 1).

Table 1. Comparison of characteristics of patients undergoing TEE facilitated early cardioversion in the studies
of Weigner et al24 and Klein et al25
Number of patients
Age, years±SD
Female sex, %
Etiology of AF, %
Hypertension
Ischemic heart disease
Valvular heart disease
Cardiomyopathy
Lone
First episode of AF, %
Estimated duration of AF
Antiarrhythmic therapy, %
History of thromboembolism, %
Left atrial thrombi on TEE, n (%)
Success electrical cardioversion, n (%)
Thromboembolic events, n (%)
AF recurrence, %
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Weigner et al24
533
72±13
46

Klein et al25
619
65±16
33

54
31
7
6
15
60
Mean: 4±9 weeks
(range: 0.3-102 weeks)
52
8.3
70/533 (13.1)
413/463 (89.2)
1 (0.2)
1 year: 57

51
NA
NA
NA
NA
NA
Median: 13 days
(range: 4-48 days)
82.2
7.9
76/549 (13.8)
344/425 (80.9)
10 (1.6)
8 weeks: 47.3
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Weigner et al 24 studied the 1-year clinical
outcome in 539 patients with AF who underwent TEE
facilitated early cardioversion to restore sinus rhythm
in patients with AF ≥2 days or of unknown duration
before cardioversion. They demonstrated that patients
with AF for less than 3 weeks were less likely to have
recurrence of AF, and were more likely to have sinus
rhythm 1 year after cardioversion. However, this study
was not a randomized study comparing the TEE strategy
with conventional therapy. The ACUTE study25 was a
multicenter, randomized, prospective trial to compare
TEE facilitated early cardioversion versus conventional
cardioversion in 1222 patients with AF ≥2 days. The
median duration of AF in both arms was 13 days. In
contrast, this study showed no significant difference in
short-term clinical outcomes between the two strategies.
Despite a significant reduction in the time to cardioversion from 31 days to 3 days and a higher initial
success rate of cardioversion with the use of TEEfacilitated early cardioversion, there was no significant
difference between the two groups in the rate of
maintenance of sinus rhythm after 8 weeks. However,
in both studies, the majority of patients had AF for >2

weeks before cardioversion. Therefore, it remains to
be shown whether even earlier cardioversion of AF
affect the initial and long-term success of cardioversion.

Repeated External Cardioversion
on AF Recurrence
In addition to using TEE to facilitate early
cardioversion, the other approach to avoid atrial
remodeling is by repeated electrical cardioversion
(Table 2). This strategy aims to maintaining patients in
sinus rhythm to promote reverse remodeling of the
atrium, which may subsequently lead to a reduction in
the subsequent likelihood of AF recurrence. Van Gelder
et al9 performed the clinical trial to evaluate the role
serial cardioversion in 236 patients with persistent AF.
In this study, patients initially underwent external
cardioversion without the use of antiarrhythmic agent,
and then serial testing of different antiarrhythmic agents
(sotalol→flecainide→amiodarone) and up to a
maximum of four cardioversions were performed in
those who had AF recurrence. The serial cardioversion

Table 2. Comparison of characteristics of patients undergoing repeat cardioversion in the studies of Van
Gelder et al,9 Fynn et al26 and Bertaglia et al27
Number of patients
Age, years
Female sex, %
Etiology of AF, %
Hypertension
Ischemic heart disease
Valvular heart disease
Other
Lone
Mean duration of AF, months
Antiarrhythmic therapy, %
Class III
Class IC
Beta-blockers
Calcium antagonists
Digoxin
Left atrial size, cm
AF recurrence, %
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Van Gelder et al9
236
63±12
44

Fynn et al26
59
60±10
29

Bertaglia et al27
45
68±8
36

17
28
33
21
22
NA

20
15
10
16
39
30±46

42
9
11
9
29
2.5±2.1

NA
NA
NA
NA
NA
4.6±8
1 year: 58
4 years: 73

8
0
15
0
0
4.04±0.5
1 month: 76

68
31
7
22
60
4.76±5.8
12 months: 47
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approach was effective to increase the duration of sinus
rhythm in a subgroup of patients with shorter duration
of AF. In a recent study, Bertaglia et al27 randomized
90 patients with persistent AF treated with either class
IC or III antiarrhythmic agents to either a single
cardioversion or a maximum of three repeated
cardioversions. In this study, the mean duration of AF
before cardioversion was 10 weeks, and the mean
duration in AF prior to the repeat cardioversion was
1 month. After 1 year follow-up, 53% of patients who
underwent repeated cardioversion were in sinus rhythm
compared to only 29% in patients with only single
cardioversion. Therefore, both studies demonstrated that
serial cardioversion is useful in maintaining sinus
rhythm in patients with persistent AF. However, in order
to maximize the benefit of this approach, serial
cardioversion should be performed early after the
occurrence of persistent or recurrent AF.
Fynn et al 26 assessed the atrial electrophysiological properties and clinical outcome in patients
with persistent AF who underwent repeated internal
cardioversion. In this study, 59 patients with persistent
AF were monitored on a daily basis for 1 month after
the initial cardioversion of AF, and were readmitted for
repeated cardioversion (up to a maximum of three times)
as soon as AF recurrence was detected. Successful
cardioversion was achieved in 55 patients (93%) and
29 of them subsequently had AF recurrence during
monitoring. In those patients who underwent repeated
internal cardioversion, their atrial effective periods
increased after serial cardioversion, suggesting reversal
of atrial electrical remodeling during this period.
However, there was no significant increase in the
duration of sinus rhythm after serial cardioversion, and
only 14 patients maintained sinus rhythm for 1 month.
The authors concluded that a policy of early repeated
cardioversion for recurrence of AF has a very limited
role, despite evidence of reversal of electrical
remodeling. The difference in the clinical outcome
between this study and those discussed above is likely
due to the difference in their patient selection and study
design (Table 2). Fynn et al27 included patients with
unfavorable arrhythmia profile with long duration of
AF (median 13 months), failed prior cardioversion
J HK Coll Cardiol, Vol 11

(13%), a higher prevalence of structural heart diseases
(61%) and only a minority were taking antiarrhythmic
medications. In patients with prolonged duration of AF
and underlying structural heart diseases, other additional
factors, such as structural remodeling and fibrosis might
be irreversible,11,12 and render the atria vulnerable to
recurrent AF despite reversal of electrical remodeling.
Furthermore, only 27 of 59 patients (48%) finally
completed the protocol as intended which limited the
sample size and thus conclusion of this study.

Effect of Prompt Cardioversion
by Implantable Device
The success of the implantable ventricular
defibrillator and internal atrial cardioversion using low
energy led to the concept of the development of
implantable devices for atrial defibrillation.28 The
implantable atrial defibrillator (IAD) is designed to
provide an effective method for early detection and
cardioversion in patients with AF, with the hope that it
might provide immediate benefits of sinus rhythm and
positively alters the progressive natural history of AF.29-31
Timmermans et al32 evaluated the effect of repeated
device-based atrial shock using an IAD on the clinical
course of the arrhythmia in patients with AF. In this
study, 51 patients with drug-refractory AF underwent
implantation of a stand-alone IAD for treatment of AF.
The majority of these patients had no structural heart
disease and normal left ventricular function. The IAD
performed periodic monitoring of AF and atrial shocks
were delivered under physician supervision during
spontaneous AF. The majority of treated AF episodes
in this study were >8 hours with a median duration of
~18 hours. After a mean of 260 days follow-up, all
patients remained in sinus rhythm, the time interval
between episodes requiring device therapy increased,
and the risk of having an episode requiring treatment
decreased. These findings suggest that repeated devicebased cardioversion for AF was effective in maintaining
sinus rhythm and progressively decreased the need for
cardioversion over time.
Tse et al33 investigated the effects of the IAD on

July 2003

94

CARDIOVERSION FOR ATRIAL FIBRILLATION

the total duration of AF, number of AF recurrences and
left atrial size in 16 patients with AF. In this study,
8 patients had paroxysmal AF and 8 patients had
persistent AF with a mean AF duration of 72±91 months.
Except for 1 patient who received digoxin, all patients
received the same class I or III antiarrhythmic agent
throughout the study. The IAD successfully converted
93% of spontaneous episodes of AF in 12 patients. After
6 month of follow-up, maintaining sinus rhythm by
repeated device-based cardioversion using IAD in
patients with persistent AF reduced the total burden of
AF and the left atrial size. These favorable effects were
not observed in patients with paroxysmal AF. The
results of this study suggest that repeated cardioversion
with an IAD might reverse the process of mechanical
atrial remodeling and modify the natural history of AF
in patients with persistent AF. It is likely that in patients
with paroxysmal AF, a significant proportion of their
AF episodes were short lasting and were not treated by
the device, therefore, IAD had a lesser impact on the
natural history of their AF.
Furthermore, the occurrence and time course of
recovery of atrial mechanical dysfunction after
cardioversion of AF appear to be related to the duration
of arrhythmia. A recent study34 in patients with IAD have
demonstrated that prompt termination of AF episodes
using device-based cardioversion may further enhance
the recovery of left atrial mechanical dysfunction as
assessed by Doppler echocardiography. At 1 minute
after cardioversion, the transmitral flow Doppler
parameters were significantly smaller during episodes
of AF treated at >48 hours than at <48 hours. At 4 hours
and 1 week after cardioversion, the mean peak A-wave
velocity and the mean deceleration of the A wave
increased during episodes of AF at <48 hours, and
became significantly greater than those during AF
episodes at <48 hours. In addition, early cardioversion
of AF using the IAD prevented AF induced left and
right ventricular dysfunction.35 These findings provide
further evidence to support a prompter cardioversion
of AF using an IAD to enhance the recovery of the atrial
and ventricular function from the mechanical
remodeling changes.
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Conclusions
Based on the available data as discusses above,
TEE facilitated cardioversion and early repeated cardioversion may be clinically valuable in some patients who
have short duration of persistent AF and recurrence of
arrhythmia after the initial cardioversion. Both studies
from Fynn et al26 and Bertaglia et al27 suggested that in
patients who have a recurrence of AF after a second
cardioversion, there is little to be gained from a third
cardioversion. A strategy of early repeated external
cardioversion for AF poses major practical problems in
both early detection and external cardioversion for
obvious logistic reasons. In the Fynn's study,26 the mean
duration in AF prior to the repeat cardioversion was 1320 hours, which is a rather long period to allow the
occurrence of atrial remodeling. Therefore, serial
cardioversion using this method may not have been
performed early enough to prevent AF recurrence.
Clinical studies 29-34 using an IAD for early
repeated device-based cardioversion to maintain sinus
rhythm have shown to be safe and clinical feasible.
Furthermore, this approach allows prompter
cardioversion of AF and has shown to reduce AF burden,
reverse atrial remodeling and prevent subsequent AF
recurrence, indicating "sinus rhythm beget sinus rhythm"
in a subgroup of selected patients without structural heart
disease implanted with this device. Despite this
encouraging initial observation, further long-term
clinical studies in a large patients population are needed
to confirm this finding. It is not known whether the use
of an IAD in patients with structural heart diseases, in
whom irreversible atrial structural changes have been
developed, might observe similar clinical benefit.
Furthermore, in these initial clinical studies of IAD,32-36
device-based cardioversion was performed under
physician supervision or patient- activated due to safety
and patient's tolerance issues. As a result, the duration
between the onset of AF and device-based cardioversion
remained long (~18 hours). Whether the use of IAD in
the fully automatic mode to provide prompter
termination of AF episodes may intensify the potential
benefit effect remains unclear.

July 2003

J HK Coll Cardiol, Vol 11

TSE AND LAU

References
1. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial
fibrillation on the risk of death: the Framingham Heart Study.
Circulation 1998;98:946-52.
2. Ryder KM, Benjamin EJ. Epidemiology and significance of
atrial fibrillation. Am J Cardiol 1999;84:131R-138R.
3. Braunwald E. Shattuck lecture – cardiovascular medicine at
the turn of the millennium: triumphs, concerns, and
opportunities. N Engl J Med 1997;337:1360-9.
4. Wang TJ, Larson MG, Levy D, et al. Temporal relations of
atrial fibrillation and congestive heart failure and their joint
influence on mortality: the Framingham Heart Study.
Circulation 2003;107:2920-5.
5. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate
control and rhythm control in patients with atrial fibrillation.
N Engl J Med 2002;347:1825-33.
6. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison
of rate control and rhythm control in patients with recurrent
persistent atrial fibrillation. N Engl J Med 2002;347:1834-40.
7. Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history
of lone atrial fibrillation. A population-based study over three
decades. N Engl J Med 1987;317:669-74.
8. Van Gelder IC, Tuinenburg AE, Schoonderwoerd BS, et al.
Pharmacologic versus direct-current electrical cardioversion of
atrial flutter and fibrillation. Am J Cardiol 1999;84:147R-151R.
9. Van Gelder IC, Crijns HJ, Tieleman RG, et al. Chronic atrial
fibrillation. Success of serial cardioversion therapy and safety
of oral anticoagulation. Arch Intern Med 1996;156:2585-92.
10. Tse HF, Lau CP, Ayers GM. Long-term outcome in patients
with chronic atrial fibrillation after successful internal
cardioversion. Am J Cardiol 1999;83:607-9.
11. Shinagawa K, Li D, Leung TK, et al. Consequences of atrial
tachycardia-induced remodeling depend on the preexisting atrial
substrate. Circulation 2002;105:251-7.
12. Verheule S, Wilson E, Everett T 4th, et al. Alterations in atrial
electrophysiology and tissue structure in a canine model of
chronic atrial dilatation due to mitral regurgitation. Circulation
2003;107:2615-22.
13. Wijffels MC, Kirchhof CJ, Dorland R, et al. Atrial fibrillation
begets atrial fibrillation. A study in awake chronically
instrumented goats. Circulation 1995;92:1954-68.
14. Nattel S. Therapeutic implications of atrial fibrillation
mechanisms: can mechanistic insights be used to improve AF
management? Cardiovasc Res 2002;54:347-60.
15. Schotten U, Neuberger HR, Allessie MA. The role of atrial
dilatation in the domestication of atrial fibrillation. Prog
Biophys Mol Biol 2003;82:151-62.
16. Tse HF, Lau CP, Ayers GM. Heterogeneous changes in
electrophysiologic properties in the paroxysmal and chronically
fibrillating human atrium. J Cardiovasc Electrophysiol 1999;
10:125-35.
17. Shimizu A, Centurion OA. Electrophysiological properties of
the human atrium in atrial fibrillation. Cardiovasc Res 2002;
54:302-14.
18. Sanfilippo AJ, Abascal VM, Sheehan M, et al. Atrial enlargement
as a consequence of atrial fibrillation. A prospective
echocardiographic study. Circulation 1990;82:792-7.
19. Lee SH, Lin FY, Yu WC, et al. Regional differences in the
recovery course of tachycardia-induced changes of atrial
electrophysiological properties. Circulation 1999;99:1255-64.

J HK Coll Cardiol, Vol 11

20. Hobbs WJ, Fynn S, Todd DM, et al. Reversal of atrial electrical
remodeling after cardioversion of persistent atrial fibrillation
in humans. Circulation 2000;101:1145-51.
21. Harjai KJ, Mobarek SK, Cheirif J, et al. Clinical variables
affecting recovery of left atrial mechanical function after
cardioversion from atrial fibrillation. J Am Coll Cardiol 1997;
30:481-6.
22. Weigner MJ, Caulfield TA, Danias PG, et al. Risk for clinical
thromboembolism associated with conversion to sinus rhythm
in patients with atrial fibrillation lasting less than 48 hours.
Ann Intern Med 1997;126:615-20.
23. Ryman J, Frick M, Frykman V, et al. Duration of warfarin
sodium therapy prior to electrical cardioversion of atrial
fibrillation. J Intern Med 2003;253:76-80.
24. Weigner MJ, Thomas LR, Patel U, et al. Early cardioversion
of atrial fibrillation facilitated by transesophageal
echocardiography: short-term safety and impact on maintenance
of sinus rhythm at 1 year. Am J Med 2001;110:694-702.
25. Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal
echocardiography to guide cardioversion in patients with atrial
fibrillation. N Engl J Med 2001;344:1411-20.
26. Fynn SP, Todd DM, Hobbs WJ, et al. Clinical evaluation of a
policy of early repeated internal cardioversion for recurrence of
atrial fibrillation. J Cardiovasc Electrophysiol 2002;13:135-41.
27. Bertaglia E, D'Este D, Zerbo F, et al. Success of serial external
electrical cardioversion of persistent atrial fibrillation in
maintaining sinus rhythm; a randomized study. Eur Heart J
2002;23:1522-8.
28. Tse HF, Lau CP, Camm AJ. Transvenous atrial defibrillation –
techniques and clinical applications. Clin Cardiol 1999;22:61422.
29. Lau CP, Tse HF, Lok NS, Lee KL, Ho DS, Sopher M,
Murgatroyd F, Camm AJ. Initial clinical experience with an
implantable human atrial defibrillator. Pacing Clin
Electrophysiol 1997;20:220-5.
30. Wellens HJ, Lau CP, Luderitz B, et al. Atrioverter: an
implantable device for the treatment of atrial fibrillation.
Circulation 1998;98:1651-6.
31. Tse HF, Lau CP, Sra JS, et al. Atrial fibrillation detection and
R-wave synchronization by Metrix implantable atrial
defibrillator: implications for long-term efficacy and safety.
The Metrix Investigators. Circulation 1999;99:1446-51.
32. Timmermans C, Levy S, Ayers GM, et al. Spontaneous episodes
of atrial fibrillation after implantation of the Metrix Atrioverter:
observations on treated and nontreated episodes. Metrix
Investigators. J Am Coll Cardiol 2000;35:1428-33.
33. Tse HF, Lau CP, Yu CM, et al. Effect of the implantable atrial
defibrillator on the natural history of atrial fibrillation.
J Cardiovasc Electrophysiol 1999;10:1200-9.
34. Tse HF, Wang Q, Yu CM, et al. Time course of recovery of
left atrial mechanical dysfunction after cardioversion of
spontaneous atrial fibrillation with the implantable atrial
defibrillator. Am J Cardiol 2000;86:1023-5.
35. Yu CM, Wang Q, Lau CP, et al. Reversible impairment of left
and right ventricular systolic and diastolic function during shortlasting atrial fibrillation in patients with an implantable atrial
defibrillator: a tissue Doppler imaging study. Pacing Clin
Electrophysiol 2001;24:979-88.
36. Daoud EG, Timmermans C, Fellows C, et al. Initial clinical
experience with ambulatory use of an implantable atrial
defibrillator for conversion of atrial fibrillation. Metrix
Investigators. Circulation 2000;102:1407-13.

July 2003

96

